Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice

Sang Don Lee; Seung Ju Lee; Tae Kon Hwang; Duck Ki Yoon; Kyu Sung Lee; Luck Hee Sung; Myung Soo Choo; Bong Suk Shim; In Rae Cho; Min Eui Kim; Soo Bang Ryu; Chul Sung Kim; Young Gon Kim; Chun Il Kim; Hyun Yul Rhew; Myung Hoon Kim; Yong Hyun Cho

doi:10.1016/j.ijantimicag.2006.05.014

Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice

Sang Don Lee, Seung Ju Lee, Tae Kon Hwang, Duck Ki Yoon, Kyu Sung Lee, Luck Hee Sung, Myung Soo Choo, Bong Suk Shim, In Rae Cho, Min Eui Kim, Soo Bang Ryu, Chul Sung Kim, Young Gon Kim, Chun Il Kim, Hyun Yul Rhew, Myung Hoon Kim, Yong Hyun Cho

Department of Urology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

To investigate the efficacy and safety of gatifloxacin (400 mg/day) on chronic prostatitis or cystitis, 453 patients with prostatitis (NIH category II or IIIa) (N = 149, mean 45.8 ± 13.3 years) and cystitis (N = 304, mean 53.8 ± 14.3 years) were enrolled. Total NIH CPSI score and symptom score for cystitis decreased from 20.3 to 9.9 (response rate 86.7%, 95% CI 80.2-93.2%) and from 6.2 to 1.8 (response rate 83.2%, 95% CI 78.7-87.7%), respectively. In the overall clinical efficacy, 71.2% and 88.4% of the patients with prostatitis and cystitis were responders, respectively. Of the patients, 15.7% reported insignificant adverse events. These results suggest that gatifloxacin was well tolerated and improved the clinical outcomes in patients with chronic prostatitis or cystitis.

Original language	English
Pages (from-to)	108-112
Number of pages	5
Journal	International Journal of Antimicrobial Agents
Volume	28
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/j.ijantimicag.2006.05.014
State	Published - Aug 2006

Bibliographical note

Funding Information:
This study was supported and funded by Handok-Aventis Pharmaceuticals, Seoul, Korea. We thank all the physicians who participated in this surveillance study.

Keywords

Cystitis
Efficacy
Gatifloxacin
Prostatitis
Safety

Access to Document

10.1016/j.ijantimicag.2006.05.014

Cite this

Lee, S. D., Lee, S. J., Hwang, T. K., Yoon, D. K., Lee, K. S., Sung, L. H., Choo, M. S., Shim, B. S., Cho, I. R., Kim, M. E., Ryu, S. B., Kim, C. S., Kim, Y. G., Kim, C. I., Rhew, H. Y., Kim, M. H., & Cho, Y. H. (2006). Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice. International Journal of Antimicrobial Agents, 28(SUPPL. 1), 108-112. https://doi.org/10.1016/j.ijantimicag.2006.05.014

@article{ce8ccd44c659448eb7b2a32a8630d448,

title = "Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice",

abstract = "To investigate the efficacy and safety of gatifloxacin (400 mg/day) on chronic prostatitis or cystitis, 453 patients with prostatitis (NIH category II or IIIa) (N = 149, mean 45.8 ± 13.3 years) and cystitis (N = 304, mean 53.8 ± 14.3 years) were enrolled. Total NIH CPSI score and symptom score for cystitis decreased from 20.3 to 9.9 (response rate 86.7%, 95% CI 80.2-93.2%) and from 6.2 to 1.8 (response rate 83.2%, 95% CI 78.7-87.7%), respectively. In the overall clinical efficacy, 71.2% and 88.4% of the patients with prostatitis and cystitis were responders, respectively. Of the patients, 15.7% reported insignificant adverse events. These results suggest that gatifloxacin was well tolerated and improved the clinical outcomes in patients with chronic prostatitis or cystitis.",

keywords = "Cystitis, Efficacy, Gatifloxacin, Prostatitis, Safety",

author = "Lee, {Sang Don} and Lee, {Seung Ju} and Hwang, {Tae Kon} and Yoon, {Duck Ki} and Lee, {Kyu Sung} and Sung, {Luck Hee} and Choo, {Myung Soo} and Shim, {Bong Suk} and Cho, {In Rae} and Kim, {Min Eui} and Ryu, {Soo Bang} and Kim, {Chul Sung} and Kim, {Young Gon} and Kim, {Chun Il} and Rhew, {Hyun Yul} and Kim, {Myung Hoon} and Cho, {Yong Hyun}",

note = "Funding Information: This study was supported and funded by Handok-Aventis Pharmaceuticals, Seoul, Korea. We thank all the physicians who participated in this surveillance study.",

year = "2006",

month = aug,

doi = "10.1016/j.ijantimicag.2006.05.014",

language = "English",

volume = "28",

pages = "108--112",

journal = "International Journal of Antimicrobial Agents",

issn = "0924-8579",

publisher = "Elsevier",

number = "SUPPL. 1",

}

Lee, SD, Lee, SJ, Hwang, TK, Yoon, DK, Lee, KS, Sung, LH, Choo, MS, Shim, BS, Cho, IR, Kim, ME, Ryu, SB, Kim, CS, Kim, YG, Kim, CI, Rhew, HY, Kim, MH & Cho, YH 2006, 'Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice', International Journal of Antimicrobial Agents, vol. 28, no. SUPPL. 1, pp. 108-112. https://doi.org/10.1016/j.ijantimicag.2006.05.014

TY - JOUR

T1 - Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice

AU - Lee, Sang Don

AU - Lee, Seung Ju

AU - Hwang, Tae Kon

AU - Yoon, Duck Ki

AU - Lee, Kyu Sung

AU - Sung, Luck Hee

AU - Choo, Myung Soo

AU - Shim, Bong Suk

AU - Cho, In Rae

AU - Kim, Min Eui

AU - Ryu, Soo Bang

AU - Kim, Chul Sung

AU - Kim, Young Gon

AU - Kim, Chun Il

AU - Rhew, Hyun Yul

AU - Kim, Myung Hoon

AU - Cho, Yong Hyun

N1 - Funding Information: This study was supported and funded by Handok-Aventis Pharmaceuticals, Seoul, Korea. We thank all the physicians who participated in this surveillance study.

PY - 2006/8

Y1 - 2006/8

N2 - To investigate the efficacy and safety of gatifloxacin (400 mg/day) on chronic prostatitis or cystitis, 453 patients with prostatitis (NIH category II or IIIa) (N = 149, mean 45.8 ± 13.3 years) and cystitis (N = 304, mean 53.8 ± 14.3 years) were enrolled. Total NIH CPSI score and symptom score for cystitis decreased from 20.3 to 9.9 (response rate 86.7%, 95% CI 80.2-93.2%) and from 6.2 to 1.8 (response rate 83.2%, 95% CI 78.7-87.7%), respectively. In the overall clinical efficacy, 71.2% and 88.4% of the patients with prostatitis and cystitis were responders, respectively. Of the patients, 15.7% reported insignificant adverse events. These results suggest that gatifloxacin was well tolerated and improved the clinical outcomes in patients with chronic prostatitis or cystitis.

AB - To investigate the efficacy and safety of gatifloxacin (400 mg/day) on chronic prostatitis or cystitis, 453 patients with prostatitis (NIH category II or IIIa) (N = 149, mean 45.8 ± 13.3 years) and cystitis (N = 304, mean 53.8 ± 14.3 years) were enrolled. Total NIH CPSI score and symptom score for cystitis decreased from 20.3 to 9.9 (response rate 86.7%, 95% CI 80.2-93.2%) and from 6.2 to 1.8 (response rate 83.2%, 95% CI 78.7-87.7%), respectively. In the overall clinical efficacy, 71.2% and 88.4% of the patients with prostatitis and cystitis were responders, respectively. Of the patients, 15.7% reported insignificant adverse events. These results suggest that gatifloxacin was well tolerated and improved the clinical outcomes in patients with chronic prostatitis or cystitis.

KW - Cystitis

KW - Efficacy

KW - Gatifloxacin

KW - Prostatitis

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=33746678552&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2006.05.014

DO - 10.1016/j.ijantimicag.2006.05.014

M3 - Article

C2 - 16844352

AN - SCOPUS:33746678552

SN - 0924-8579

VL - 28

SP - 108

EP - 112

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

IS - SUPPL. 1

ER -

Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this